CD82
CD82 antigen
Also known as: CD82_HUMAN, IA4, KAI1, R2, ST6, TSPAN27
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P27701
- Gene
- CD82
- Ensembl
- ENSG00000085117
- Chromosome
- 11
- Canonical length
- 267 aa
- Protein class
- Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Vesicles
- Quaternary structure
- Homooligomer
OverviewNCBI Gene
This metastasis suppressor gene product is a membrane glycoprotein that is a member of the transmembrane 4 superfamily. Expression of this gene has been shown to be downregulated in tumor progression of human cancers and can be activated by p53 through a consensus binding sequence in the promoter. Its expression and that of p53 are strongly correlated, and the loss of expression of these two proteins is associated with poor survival for prostate cancer patients. Two alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
267 residues, UniProt reviewed canonical sequence.
>P27701|CD82
1 MGSACIKVTK YFLFLFNLIF FILGAVILGF GVWILADKSS FISVLQTSSS SLRMGAYVFI
61 GVGAVTMLMG FLGCIGAVNE VRCLLGLYFA FLLLILIAQV TAGALFYFNM GKLKQEMGGI
121 VTELIRDYNS SREDSLQDAW DYVQAQVKCC GWVSFYNWTD NAELMNRPEV TYPCSCEVKG
181 EEDNSLSVRK GFCEAPGNRT QSGNHPEDWP VYQEGCMEKV QAWLQENLGI ILGVGVGVAI
241 IELLGMVLSI CLCRHVHSED YSKVPKYLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CD82 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 4
- Mean surface accessibility (rSASA)
- 0.33
- Highest tissue expression
- 136 nTPM
Expression across tissuesHPA
Tissue
- esophagus: 136 nTPM
- bone marrow: 132 nTPM
- lung: 89 nTPM
- skin: 89 nTPM
- tonsil: 77 nTPM
- small intestine: 77 nTPM
Single-cell type
- neutrophils: 552 nCPM
- esophageal suprabasal cells: 393 nCPM
- esophageal basal cells: 269 nCPM
- esophageal apical cells: 254 nCPM
- mast cells: 244 nCPM
- prostatic club cells: 230 nCPM
Immune cell
- neutrophil: 537 nTPM
- basophil: 367 nTPM
- memory B-cell: 309 nTPM
- naive B-cell: 211 nTPM
- T-reg: 173 nTPM
- memory CD4 T-cell: 150 nTPM
Brain region
- thalamus: 157 nTPM
- basal ganglia: 152 nTPM
- midbrain: 140 nTPM
- white matter: 123 nTPM
- medulla oblongata: 108 nTPM
- cerebral cortex: 97 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.25
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.09
- DepMap mean gene effect
- 0.05
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of CD82 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CD82 as an antibody target. Whether an autoantibody or antibody against CD82 could matter depends on whether native CD82 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CD82 is annotated at the cell surface, where native CD82 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label CD82 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...